Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of NRT6003 versus conventional TACE in unresectable hepatocellular carcinoma
CTR20250792Phase 3Active
- Sponsor
- Chengdu Newray Medical Technology
- Start
- Apr 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of TareSphere in hepatocellular carcinoma (HCC) (2 arms), sponsored by Chengdu Newray Medical Technology. Primary endpoint: Time to progression. Started Apr 2025; status: active.
02
Drugs
TareSphere
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20250792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250792.